| Place of Origin: | CHINA |
|---|---|
| Brand Name: | TINGYI |
| Certification: | GMP , ISO 9001:2008 |
| Model Number: | 139264-17-8 |
| Minimum Order Quantity: | 10g |
| Price: | Contact Me |
| Packaging Details: | Disguised Package |
| Delivery Time: | 2 Working Days |
| Payment Terms: | Bank Transfer - Bitcoin - Western Union - MoneyGram |
| Supply Ability: | 100 KG/Month |
| Product Name: | Zolmitriptan | CAS: | 139264-17-8 |
|---|---|---|---|
| Appearance: | White Powder | Usage: | Anti-migraine |
| Shipping Method: | EMS, HKEMS, FEDEX, DHL, UPS, Aramex, ETC | Color: | White |
| High Light: | pharmaceutical active ingredients,pharmaceutical anabolic steroids |
||
Basic Information
| Product Name | Zolmitriptan |
| CAS | 139264-17-8 |
| Purity | 99% |
| Molecular Formula | C16H21N3O2 |
| Molecular Weight | 287.35684 |
| EINECS | 629-919-0 |
| Molecular Structure |  |
| Payment Method |
Western Union, Bank Transfer, MoneyGram, Bitcoin, Litecoin
|
COA
| Item | Standard | Result |
| Appearance | white to off-white powder | off-white powder |
| solubility | soluble in methanol | complies |
| identification | IR/HPLC | complies |
| Melting range | 136~141deg.C | 136.6~138.5Deg.C% |
| a[D] | -4.5~-8.5Deg | -6.2deg |
| redisue on ignition | 0.1% max | 0.05% |
| Heavy metals | 10ppm max | complies |
| loss on drying | 0.5% max | 0.25% |
| related substaces | ||
| single impurity | 0.5% max | 0.15% |
| total impurity | 1.0% max | 0.31% |
| Assay | 99%-101.5% | 99.90% |
Medical uses
Zolmitriptan is used for the acute treatment of migraines with or without aura in adults. Zolmitriptan is not intended for the prophylactic therapy of migraine or for use in the management of hemiplegic or basilar migraine.
Zolmitriptan is available as a swallowable tablet, an oral disintegrating tablet, and a nasal spray, in doses of 2.5 and 5 mg. People who get migraines from aspartame should not use the disintegrating tablet (Zomig ZMT), which contains aspartame.
According to a study of healthy volunteers, food intake seems to have no significant effect on the effectiveness of Zolmitriptan in both men and women.
Contraindications and precautions
Zolmitriptan should not be given to patients with ischemic heart disease (angina pectoris, history of myocardial infarction, or documented silent ischemia) or to patients who have symptoms or findings consistent with ischemic heart disease, coronary artery vasospasm, including Prinzmetal's angina, or other significant underlying cardiovascular disease.
Zolmitriptan may increase blood pressure, it should not be given to patients with uncontrolled hypertension, should not be used within 24 hours of treatment with another 5-HT1 agonist, or an ergotamine-containing or ergot-type medication like dihydroergotamine or methysergide, and should not be administered to patients with hemiplegic or basilar migraine.
Concurrent administration of MAOI or use of zolmitriptan within 2 weeks of discontinuation of MAO-A inhibitor therapy is contraindicated.
Adverse reactions
The Zomig ZMT dissolvable pill contains aspartame, and should be avoided by anyone sensitive to that ingredient and by those suffering from phenylketonuria.
Rarely, serious cardiac events, including myocardial infarction (heart attack), have been associated with zolmitriptan.
Reported minor adverse reactions include: hypesthesia, paresthesia (all types), warm and cold sensations, chest pain, throat and jaw tightness, dry mouth, dyspepsia, dysphagia, nausea, somnolence, vertigo, asthenia, myalgia, myasthenia and sweating.
Following administration of cimetidine, the half-life and AUC of zolmitriptan and its active metabolites were approximately doubled (see CLINICAL PHARMACOLOGY in product pamphlet). Cimetidine is a histamine H2-receptor antagonist that inhibits the production of acid in the stomach.
Chemistry
Zolmitriptan is a synthetic tryptamine derivative and appears as a white powder that is partially soluble in water.
